Maternal serum calcitriol during pregnancy and risk of childhood onset type 1 diabetes
- 270 Downloads
Vitamin D seems to play a role in immunity at the feto-maternal interface by influencing decidual macrophages, dendritic cells, and other leukocytes , and maternal vitamin D status in pregnancy may have long-term effects on the fetus . Previously we reported that low concentrations of maternal levels of 25-hydroxyvitamin D (25-OH D) and vitamin D-binding protein (DBP) during pregnancy may be related to higher risk of type 1 diabetes (T1D) in the offspring, in a case–control study nested within nearly 30,000 pregnancies .
25-OH D is considered the clinical relevant marker of vitamin D status although calcitriol, or 1,25-dihydroxyvitamin D (1,25-(OH)2 D), is the active hormone binding to the vitamin D receptor. Epidemiological studies suggest that the two vitamin D metabolites may be similarly correlated with some outcomes, but differentially correlated with other outcomes such as different inflammatory markers . Calcitriol is known to increase substantially in pregnancy,...
Thanks to The Norwegian Childhood Diabetes Registry for data on children with type 1 diabetes, and Tone Kvalvik at the Hormone laboratory, Oslo University Hospital for 1,25-dihydroxyvitamin D analyses.
This study was supported by grants from the South-East Regional Health Authority of Norway, the Research Unit at Women and Children’s Division at Oslo University Hospital Ullevål and by Oslo Diabetes Research Centre.
IMS, LCS, and GJ designed and conducted the research. IMS and LCS analyzed the data. LCS performed the statistical analysis. PAJ and AE organized the original cohort. SRD provided essential reagents. IMS and LCS wrote the article. All authors commented on the manuscript, and LCS is the guarantor of this work.
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflict of interest.
Human and animal rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent was obtained from all patients for being included in the study.